Oncoimmunology

Article	Citations
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization	97
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	96
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	80
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	63
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	62
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	61
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	59
Ferroptosis: friend or foe in cancer immunotherapy?	58
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	56
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	55
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	55
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	53
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	50
Correction	48
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 + T cells eradicates peritoneal metastases in mouse models	46
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	44
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	41
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	41
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	38
STING is significantly increased in high-grade glioma with high risk of recurrence	37
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	37
CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	37
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	36
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	36
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	35

Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	34
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	33
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	33
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	33
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	33
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	33
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid	32
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	32
Immune sunrise: from the immunome to the cancer immune landscape	31
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab	31
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue	31
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	31
Reprogramming monocyte-derived macrophages through caspase inhibition	31
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy	29
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	29
Liver metastases of colorectal cancer contain different subsets of tissue-resident memory CD8 T cells correlated with a distinct risk of relapse following surgery	29
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors	28
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination	28
Immunogenic stress induced by local anesthetics injected into neoplastic lesions	28
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation	28
Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling	28
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis	27
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion	27
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases	27
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 + T cell function	27
Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer	27
Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade	26
Trial watch: beta-blockers in cancer therapy	26
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors	26
The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology	26
Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer	26
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy	26
A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors	26
Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML	25
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8 + T cells towards the center of human lung tumors	25
Cell therapy for a rare disease- hairy cell leukemia variant	25
Spermidine rejuvenates T lymphocytes and restores anticancer immunosurveillance in aged mice	24
Candidate tumor-specific CD8 + T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis	23
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response	23
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors	23
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers	23
Targeting coagulation to unlock antitumor immunity?	23
M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance	22
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response	22
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes	22
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)	22
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy	21
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products	21
Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia	21
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy	20

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 + T cells in vivo	20
Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue	20
CD8 + T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance	20
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma	20
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	20
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)	20
Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade	20
Schweinfurthin induces ICD without ER stress and caspase activation	20
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	19
CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies	19
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	19
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer	19
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	19
Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer	19
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction	18
Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma	18
Cell type-specific induction of ferroptosis to boost antitumor immunity	18
Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting	18
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer	18
Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression	18
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis	18
BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro	18
Enriched circulating and tumor-resident TGF-β + regulatory B cells in patients with melanoma promote FOXP3 + Tregs	18
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma	18
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood	17
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy	17
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition	17
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis	17
Piezo1 facilitates optimal T cell activation during tumor challenge	17
High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils	17
Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo	17
Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment	17
Regional immune mechanisms enhance efficacy of an autologous cellular cancer vaccine with intraperitoneal administration	17
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies	17
LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors	17
Arsenic trioxide as an inducer of immunogenic cell death	17
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden	17
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment	16
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome	16
Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases	16
CD4+ T cell-derived IL-22 enhances liver metastasis by promoting angiogenesis	16
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor cells inhibit T-cell function	16
Non-pharmaceutical interventions to optimize cancer immunotherapy	16
How macrophages use extracellular calreticulin to chase their prey	15
CD4 + tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts	15
Single-cell analysis of T lymphocytes infiltrating colorectal carcinoma: the dilemma of specificity	15
Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death	15
Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?	15
Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis	15
Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I int	14
Tumor-associated macrophages promote intratumoral conversion of conventional CD4 + T cells into regulatory T cells via PD-1 signalling	14
Cross-disease integration of single-cell RNA sequencing data from lung myeloid cells reveals TAM signature in in vitro model	14
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses	14
An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer	14
Human allogenic γδ T cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands	14
CD25 bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression	13
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor	13
Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer	13
EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity	13
The landscape of T-cell engagers for the treatment of follicular lymphoma	13
Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models	13
Immunotherapy approaches for the treatment of diffuse midline gliomas	13
Type I interferon induces cancer stem cells-mediated chemotherapy resistance	13
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer	13
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer	13
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival	13
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors	13
Metabolic regulation of the mitochondrial immune checkpoint	13
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody	13
Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer	13
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma	12
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response	12
Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion	12
Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137	12
Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site	12
Vasculogenic mimicry structures in melanoma support the recruitment of monocytes	12
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome	12
Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma	12
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases	12
Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma	12

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma	12
ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer	12
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	12
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function	12
Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma	12
Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-β-activated kinase 1	12
Leptin decreases Th17/Treg ratio to facilitate neuroblastoma via inhibiting long-chain fatty acid catabolism in tumor cells	12
DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway	11
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer	11
Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer	11
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes	11
PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma	11
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma	11
A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin	11
A mitochondrial checkpoint to adaptive anticancer immunity	11
Nanoparticles releasing immunogenic cell death inducers upon near-infrared light exposure	11
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)	11
TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor	10
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	10
Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression	10
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells	10
Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response	10
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer	10
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors	10
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells	10
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy	10
ADA/CD26 axis increases intra-tumor PD-1 + CD28 + CD8 + T-cell fitness and affects NSCLC progno	10
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody	10
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer	10
Cellular senescence enhances adaptive anticancer immunosurveillance	10
An oncogene regulating chromatin favors response to immunotherapy	10
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression	10
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma	10
Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome	10
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients	9
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma	9
Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes	9
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer	9
RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-κB-dependent mechanism	9
Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody	9
Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer	9
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy	9
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer	9
Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells	9
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology	9
Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma	9
Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs	9
C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer	9
Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism	9
Eribulin mesylate exerts antitumor effects via CD103	9
Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients	9
Correction	9
S100A10 promotes cancer metastasis via recruitment of MDSCs within the lungs	9
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development	8
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment	8
Smad7 is a negative regulator of immunogenic cell death in colorectal cancer	8
Paradoxical control of multifocal mammary oncogenesis by radiation therapy	8
T-cell dysfunction in natural killer/T-cell lymphoma	8
A role for EMT in CD73 regulation in breast cancer	8
Correction	8
CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy	8
Immune modulation following α and β − radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model	8
Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses	8
Targeting the atypical chemokine receptor 2 ( Ackr2 ) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model	8
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality	8
Generation and functional characterization of a multigene-modified NK101 cell line exerting diverse mechanisms of antitumor action	8
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma	8
Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer	8
Anti-CD122 antibody restores specific CD8 + T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth	8
HLA class II neoantigen presentation for CD4 + T cell surveillance in HLA class II-negative colorectal cancer	8
The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis	8
PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma	7
Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer	7
Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers	7
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease	7
Studying TIGIT activity against tumors through the generation of knockout mice	7
Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression	7
Immune priming and induction of tertiary lymphoid structures in a cord-blood humanized mouse model of gastrointestinal stromal tumor	7
Principles of risk assessment in colon cancer: immunity is key	7
Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine	7
RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug	7
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis	7
Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment	6
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment	6
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities	6
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer	6
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes	6
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies	6
Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties	6
Group 2 innate lymphoid cells boost CD8 + T-cell activation in anti-tumor immune responses	6
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies	6
CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells	6
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype	6
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	6
Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060)	6